Indian pharma has little reason to fear Trump

Indian pharmaceutical firms have a long history of supplying affordable medicines to American patients. President Donald Trump's proposed tariffs on generic drugs would face significant challenges in implementation, as they would likely be passed on to American patients and the healthcare system. The levies could increase prescription-drug spending by 8% to 15%, and unprofitable production could lead to shortages of essential medications.

While some Indian firms have invested in US manufacturing for higher-margin treatments, these are not reactions to the tariff threat. If the goal is greater drug supply resilience, targeted incentives, diversified supply chains, and guaranteed purchasing contracts would be more effective than imposing tariffs on imported generics.

Until Washington shows commitment to undoing the system that rewarded cheap drug suppliers, Indian firms have little reason to worry about the tariffs.